Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Myovant Sciences Ltd (MYOV)

Myovant Sciences Ltd (MYOV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,423,342
  • Shares Outstanding, K 90,142
  • Annual Sales, $ 0 K
  • Annual Income, $ -288,990 K
  • 60-Month Beta 2.40
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.68
  • Number of Estimates 3
  • High Estimate -0.60
  • Low Estimate -0.79
  • Prior Year -0.89
  • Growth Rate Est. (year over year) +23.60%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.81 +7.56%
on 07/31/20
20.49 -22.25%
on 07/06/20
-4.10 (-20.47%)
since 07/02/20
3-Month
11.32 +40.72%
on 05/05/20
22.07 -27.80%
on 06/24/20
+4.24 (+36.27%)
since 05/04/20
52-Week
4.14 +284.78%
on 10/29/19
22.07 -27.80%
on 06/24/20
+9.03 (+130.87%)
since 08/02/19

Most Recent Stories

More News
Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Phase 3 LIBERTY Studies in Women with Uterine Fibroids and from Ovulation Inhibition Study

-- Data from Phase 3 LIBERTY program show improvement in patient-reported outcomes in addition to improvement in hemoglobin levels in anemic women

MYOV : 15.93 (+0.89%)
Myovant's Endometriosis Pain Drug Meets Goal in Study, Stock Up

Myovant (MYOV) reports positive top-line data from the phase III study on the relugolix combination therapy in women suffering from pain associated with endometriosis.

EBS : 122.63 (+3.92%)
AKCA : 11.19 (+2.47%)
MYOV : 15.93 (+0.89%)
AYTU : 1.4300 (-1.38%)
Company News for Jun 24, 2020

Companies In The News Are: SPR, BA, EA, TBIO, SNY, MYOV.

BA : 165.07 (+1.73%)
SNY : 51.79 (-2.67%)
SPR : 19.13 (-1.85%)
TBIO : 15.39 (-2.04%)
EA : 146.32 (+2.78%)
MYOV : 15.93 (+0.89%)
Thinking about trading options or stock in Fastly Inc, Myovant Sciences, Tesla, Spotify, or MGM Resorts?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FSLY, MYOV, TSLA, SPOT, and MGM.

MGM : 16.72 (+2.45%)
MYOV : 15.93 (+0.89%)
Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis

Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced top-line results from SPIRIT 1, the second of two Phase 3 studies of once-daily relugolix...

MYOV : 15.93 (+0.89%)
Sumitovant Biopharma Announces Priority Review and FDA Acceptance of Myovant Sciences New Drug Application for Once-Daily, Oral Relugolix for Advanced Prostate Cancer

- Priority Review status expected to accelerate review, with a target FDA action date of December 20, 2020

MYOV : 15.93 (+0.89%)
Myovant Sciences to Host Webcast and Conference Call at 8:30 am Eastern Time Tuesday, June 23 to Discuss Results from Phase 3 SPIRIT 1 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis

Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it will host a webcast and conference call to discuss top-line results from the...

MYOV : 15.93 (+0.89%)
Myovant Sciences Announces Priority Review and FDA Acceptance of New Drug Application for Once-Daily, Oral Relugolix for Advanced Prostate Cancer

-- Priority Review status expected to accelerate review, with a target FDA action date of December 20, 2020

MYOV : 15.93 (+0.89%)
Worried About a Weak Dollar? Here's How to Trade & Win

The ultra-easy Fed policy and widening U.S. deficit are likely to keep the greenback subdued in this coming days.

AAPL : 438.66 (+0.67%)
BHP : 54.16 (+0.88%)
TXN : 132.23 (+2.25%)
PG : 133.79 (+1.90%)
YUM : 91.82 (+0.99%)
NEM : 70.25 (+3.08%)
FXE : 111.26 (+0.34%)
GMO : 0.2345 (-1.76%)
UUP : 25.19 (-0.36%)
ADAP : 8.92 (-1.44%)
UDN : 21.10 (+0.38%)
TLND : 36.50 (+0.11%)
ADNT : 17.63 (+2.98%)
MYOV : 15.93 (+0.89%)
WPM : 56.13 (+5.89%)
Myovant Eyes Relugolix Combo Approval for Uterine Fibroids

Myovant (MYOV) submits a regulatory application with the FDA seeking approval for oral relugolix combination regimen as a treatment for heavy menstrual bleeding associated with uterine fibroids.

JNJ : 147.22 (-0.09%)
ABBV : 94.29 (-1.72%)
MYOV : 15.93 (+0.89%)
TAK : 18.37 (-0.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade MYOV with:

Business Summary

Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral...

See More

Key Turning Points

2nd Resistance Point 16.33
1st Resistance Point 16.13
Last Price 15.93
1st Support Level 15.60
2nd Support Level 15.26

See More

52-Week High 22.07
Last Price 15.93
Fibonacci 61.8% 15.22
Fibonacci 50% 13.10
Fibonacci 38.2% 10.99
52-Week Low 4.14

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar